Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

J.P. Morgan Lowers Pediatrix to 'Underweight'


J.P. Morgan downgraded Pediatrix Medical (PDX) to underweight.

The U.S. Attorney General is investigating the company's billing practices, and the Federal Trade Commission is looking into Pediatrix's merger with Magella Healthcare. Analyst Matt Ripperger says Pediatrix will likely underperform small/mid-cap healthcare services stocks until these inquiries are completed. He notes the current billing probe is nationwide, not state-specific, as in past cases, indicating the Attorney General continues to have issue with Pediatrix's business model.

Ripperger sees a fundamental risk; that physicians may become too conservative in their billing in response to this investigation. He sees 77 cents second-quarter earnings per share, $3.25 for 2003, and $3.80 for 2004.


The Aging of Abercrombie & Fitch
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus